StreetInsider.com News Articles

Form SCHEDULE 13D/A ALX ONCOLOGY HOLDINGS Filed by: venBio Global Strategic Fund, L.P.

Fri, 16 Oct 2026 21:21:00 -0400

si-local-file:///var/storage/secattach/20261016/27199059.html

Form 8-K ALX ONCOLOGY HOLDINGS For: Oct 14

Thu, 15 Oct 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20261015/27193997.html

ALX Oncology publishes Phase 2 gastric cancer trial data in Nature Medicine

Mon, 28 Sep 2026 08:01:00 -0400

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced the publication of clinical data from its ASPEN-06 randomized Phase 2 trial in Nature Medicine, evaluating evorpacept in patients with previously treated HER2-positive advanced gastric cancer or gastroesophageal junction cancer.

The trial enrolled 127 adult patients and compared evorpacept combined with trastuzumab, ramucirumab, and paclitaxel against the same three-drug regimen alone. In the intent-to-treat population, the evorpacept combination achieved an objective response rate of 40.3%, compared with 26.6% for the control arm.

Among patients with retained HER2-positive disease, the response rate rose to 48.9% versus 25.0% for the control. Post-hoc biomarker analyses identified CD47 expression

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

Mon, 28 Sep 2026 08:00:00 -0400

Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease

Subgroup analyses support CD47 expression as a predictive biomarker

ASPEN-06 clinical findings further validate Company’s biomarker-driven development strategy and reinforce its continued advancement in the ongoing Phase 2 ASPEN-09-Breast clinical trial

On track for mid-2027 topline data readout from 80 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer

ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

Mon, 28 Sep 2026 08:00:00 -0400

Subgroup analyses support CD47 expression as a predictive biomarker

ASPEN-06 clinical findings further validate Company’s biomarker-driven development strategy and reinforce its continued advancement in the ongoing Phase 2 ASPEN-09-Breast clinical trial

ALX Oncology to Present at Upcoming Investor Conferences in September

Wed, 02 Sep 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.

The details of the meetings are as follows:

Wells Fargo 21^st Annual Healthcare Conference

Format: Fireside Chat and One-on-one Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA
Time of Fireside Chat Presentation: 3:45 PM ET
Webcast link: Available here

ALX Oncology to Present at Upcoming Investor Conferences in September

Wed, 02 Sep 2026 08:00:00 -0400

The details of the meetings are as follows:

Wells Fargo 21^st Annual Healthcare Conference

Format: Fireside Chat and One-on-one Meetings
Date: Wednesday, September 9, 2026
Location: Boston, MA
Time of Fireside Chat Presentation: 3:45 PM ET
Webcast link: Available here

Form 4 ALX ONCOLOGY HOLDINGS For: Aug 17 Filed by: Lettmann Jason

Tue, 18 Aug 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260818/26945671.html

Form 4 ALX ONCOLOGY HOLDINGS For: Aug 17 Filed by: Lettmann Jason

Tue, 18 Aug 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260818/26945671.html

Form 4 ALX ONCOLOGY HOLDINGS For: Aug 17 Filed by: Wong Shelly

Tue, 18 Aug 2026 17:50:00 -0400

si-local-file:///var/storage/secattach/20260818/26945668.html

Form 4 ALX ONCOLOGY HOLDINGS For: Aug 17 Filed by: Wong Shelly

Tue, 18 Aug 2026 17:50:00 -0400

si-local-file:///var/storage/secattach/20260818/26945668.html

Form SCHEDULE 13G/A ALX ONCOLOGY HOLDINGS Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26931381.html

Form SCHEDULE 13G/A ALX ONCOLOGY HOLDINGS Filed by: TCG Crossover GP II, LLC

Fri, 14 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260814/26931381.html

Form 10-Q ALX ONCOLOGY HOLDINGS For: Jun 30

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883327.html

Form 10-Q ALX ONCOLOGY HOLDINGS For: Jun 30

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883327.html

ALX Oncology Holdings Inc. (ALXO) Tops Q2 EPS by 4c

Thu, 06 Aug 2026 08:34:45 -0400

ALX Oncology Holdings Inc. (NASDAQ: ALXO) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on ALX Oncology Holdings Inc. (ALXO) click here.

Form 8-K ALX ONCOLOGY HOLDINGS For: Aug 06

Thu, 06 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26879368.html

Form 8-K ALX ONCOLOGY HOLDINGS For: Aug 06

Thu, 06 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26879368.html

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 08:00:00 -0400

– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer –

– Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept –

– Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 –

– Strengthened leadership team with the appointments of Scott Garland as Chairman of

ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 06 Aug 2026 08:00:00 -0400

– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer –

– Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept –

– Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 –

– Strengthened leadership team with the appointments of Scott Garland as Chairman of

Form SCHEDULE 13G ALX ONCOLOGY HOLDINGS Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400
si-local-file:///var/storage/secattach/20260727/26819947.html

Form SCHEDULE 13G ALX ONCOLOGY HOLDINGS Filed by: BlackRock, Inc.

Mon, 27 Jul 2026 16:26:00 -0400
si-local-file:///var/storage/secattach/20260727/26819947.html

Form 4 ALX ONCOLOGY HOLDINGS For: Jul 01 Filed by: Wong Shelly

Mon, 06 Jul 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260706/26735991.html

Form 4 ALX ONCOLOGY HOLDINGS For: Jul 01 Filed by: Wong Shelly

Mon, 06 Jul 2026 16:31:00 -0400
si-local-file:///var/storage/secattach/20260706/26735991.html

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Tue, 30 Jun 2026 16:40:00 -0400

SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 500,000 shares of ALX Oncology’s common stock to Michael Listgarten, General Counsel, on June 29, 2026 in connection with the commencement of his employment. Mr. Listgarten’s inducement stock option is subject to the terms of